Payment overview · 2025
General Payments
$611.03
29 reported records · 9 companies
Healthcare provider profile · identity verified
Bruce Lamar Kent, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WETUMPKA, AL · NPI 1336229608
Verified facts
What the public records show
CMS Open Payments records show Bruce Lamar Kent, M.D. received $611.03 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.96 | 27.0% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.28 | 16.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $75.27 | 12.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.35 | 10.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.81 | 9.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.83 | 7.8% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $44.93 | 7.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.00 | 5.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.60 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $611.03 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $164.96 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $148.11 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $75.27 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.81 | 2 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $44.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 769 | 85 |
| Alprazolam | Alprazolam | 474 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 111 |
| Gabapentin | Gabapentin | 340 | 104 |
| Tramadol Hcl | Tramadol Hcl | 328 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 95 |
| Montelukast Sodium | Montelukast Sodium | 289 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 93 |
| Losartan Potassium | Losartan Potassium | 245 | 74 |
| Omeprazole | Omeprazole | 236 | 66 |
| Lisinopril | Lisinopril | 225 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 218 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 60 |
| Carvedilol | Carvedilol | 195 | 62 |
| Meloxicam | Meloxicam | 187 | 71 |
| Celecoxib | Celecoxib | 183 | 50 |
| Metformin Hcl | Metformin Hcl | 181 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 175 | 21 |
| Trazodone Hcl | Trazodone Hcl | 172 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 54 |
| Clonazepam | Clonazepam | 161 | 23 |
| Farxiga | Dapagliflozin Propanediol | 147 | 33 |
| Ezetimibe | Ezetimibe | 146 | 49 |
| Famotidine | Famotidine | 146 | 42 |
| Bupropion Xl | Bupropion Hcl | 130 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 40 |
| Buspirone Hcl | Buspirone Hcl | 125 | 41 |
| Furosemide | Furosemide | 121 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 119 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 19 |
| Alendronate Sodium | Alendronate Sodium | 105 | 31 |
| Potassium Chloride | Potassium Chloride | 102 | 36 |
| Simvastatin | Simvastatin | 102 | 28 |
| Eliquis | Apixaban | 100 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 27 |
| Metformin Hcl Er | Metformin Hcl | 96 | 35 |
| Ramipril | Ramipril | 94 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 29 |
| Jardiance | Empagliflozin | 90 | 20 |
| Lorazepam | Lorazepam | 89 | 14 |
| Pregabalin | Pregabalin | 89 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | suppressed |
| Ozempic | Semaglutide | 85 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 26 |
| Donepezil Hcl | Donepezil Hcl | 76 | 22 |
| Atenolol | Atenolol | 75 | 20 |
| Myrbetriq | Mirabegron | 74 | 21 |
| Fluconazole | Fluconazole | 73 | 52 |
| Mounjaro | Tirzepatide | 73 | 11 |
| Trulicity | Dulaglutide | 68 | 13 |
| Linzess | Linaclotide | 67 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 65 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 19 |
| Mirtazapine | Mirtazapine | 64 | 24 |
| Spironolactone | Spironolactone | 64 | 21 |
| Diazepam | Diazepam | 62 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 13 |
| Doxepin Hcl | Doxepin Hcl | 58 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 17 |
| Meclizine Hcl | Meclizine Hcl | 57 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 50 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 42 |
| Synthroid | Levothyroxine Sodium | 47 | 17 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Dutasteride | Dutasteride | 45 | 17 |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Rybelsus | Semaglutide | 45 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | 12 |
| Baclofen | Baclofen | 42 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 14 |
| Methocarbamol | Methocarbamol | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Mupirocin | Mupirocin | 39 | 22 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | 13 |
| Methylprednisolone | Methylprednisolone | 37 | 25 |
| Topiramate | Topiramate | 37 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 12 |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 13 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Primidone | Primidone | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 18 |
| Azithromycin | Azithromycin | 28 | 27 |
| Estradiol | Estradiol | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Prednisone | Prednisone | 17 | 11 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $611.03 · 29 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Da Vinci Surgical System, REXULTI, VRAYLAR, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error